9th MASH Drug Development Summit

Media Partnership 

between Fibrosis and 9th MASH Drug Development Summit

The MASH therapeutic landscape is entering a transformative era. With Madrigal’s Rezdiffra paving the way as the first approval, the need for more comprehensive, patient-centered solutions has never been clearer. As the pipeline surges with new therapies, the race is on to unlock innovative mechanisms of action, integrate advanced biomarkers, and refine combination and sequential approaches to deliver best-in-class treatments.

The 9th MASH Drug Development Summit is the definitive meeting point for leading pharma, pioneering biotechs, and research experts shaping the future of MASH drug development. Join 60+ MASH scientists and drug developers - including thought leaders from Eli Lilly, AstraZeneca, Pfizer, Takeda, Madrigal, Akero Therapeutics, 89 Bio, and more, as they share groundbreaking strategies to overcome the most pressing translational and clinical challenges.

From non-invasive biomarker development and patient-centric trial design to the therapeutic promise of GLP-1s and innovative combination regimens, this year’s agenda is designed to accelerate progress from discovery to clinic.

Be part of this critical forum to exchange ideas, spark collaborations, and advance meaningful therapies that have the power to transform patient lives. Find out more in the full event guide:  https://ter.li/ej3u70